Neurogenomics Market Size is valued at USD 1.7 Bn in 2024 and is predicted to reach USD 7.3 Bn by the year 2034 at a 16.2% CAGR during the forecast period for 2025-2034.
Neurogenomics is the study of how an organism's genome influences the development, structure, and function of its nervous system. It integrates neuroscience, genomics, and bioinformatics to explore how genes and their interactions shape neural processes, behaviours, and neurological disorders. Unlike neurogenetics, which focuses on single genes, neurogenomics examines genome-wide interactions, including transcriptomes, proteomes, and epigenomes, to provide a systems-level understanding of the brain.
The growing prevalence of neurological disorders, the falling cost of sequencing, and the growing application of advanced sequencing technologies in precision medicine and disease diagnostics are all driving the growth of the neurogenomics market. Furthermore, it is projected that rising awareness of neurological conditions, developing nations, and the expanding use of targeted medications would open up new opportunities for market players.
However, the market's expansion is being held back by the high cost of neurogenomics products, the poor likelihood of finding positive, actionable mutations for precision medicine, and the moral and legal concerns surrounding sequencing-based diagnosis. Additionally, rising R&D costs for pharmaceutical companies and better reimbursement and regulatory frameworks for gene sequencing are opening up new avenues for the near-term expansion of the neurogenomics market.
Competitive Landscape
Some Major Key Players In The Neurogenomics Market:
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Hoffmann-La Roche Ltd.
- Danaher Corporation
- Qiagen N. V.
- Agilent Technologies Inc.
- Oxford Nanopore Technologies Plc.
- Revvity Inc.
- Pacific Biosciences of California Inc.
- MGI Tech Co. Ltd.
- Other Market Players
Market Segmentation:
The Neurogenomics market is segmented based on offering, application, and end-user. Based on offering, the market consists of next-generation sequencing (NGS) [systems, kits & reagents (DNA extraction and amplification kits & reagents, library preparation and target enrichment kits & regents, quality control kits & reagents, other NGS kits & reagents)], polymerase chain reaction (PCR) [systems, kits & reagents (microarray+, readers & scanners, DNA and RNA microarray kits & reagents, protein microarray kits & reagents, tissue microarray kits & reagents)], and software & services. By application, the market is segmented into variant discovery, research applications, target identification, transcription factor binding analysis, functional studies, and clinical applications. By end-user, the market is segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, and academic & research institutes.
Based On The Offering, The Next-Generation Sequencing (NGS) Segment Is Accounted As A Major Contributor To The Neurogenomics Market
The Next-Generation Sequencing (NGS) category is expected to hold a major global market share in 2024 because of the steady demand for consumables and the growing number of clinical and research uses for sequencing. The growing popularity of sequencing-based diagnostic techniques reinforces NGS's leading position. Additionally, the decrease in costs associated with NGS has made it possible for a greater number of labs and research institutions to use it, which has increased its acceptability. The potential of NGS to provide a wealth of genetic data facilitates the development of specialized treatment plans for neurological disorders. Furthermore, continuous advancements in NGS technologies have improved their accuracy and capability, making them invaluable resources for neurogenomics research.
Pharmaceutical & Biotechnology Companies Segment To Witness Growth At A Rapid Rate
The pharmaceutical & biotechnology key players held the largest share of the neurogenomics market because of their widespread use of state-of-the-art technologies for research and the huge amount of financing available for such endeavours. The increasing use of next-generation sequencing in drug research and development is one of the primary factors contributing to this industry's domination. Businesses are making significant investments in genomics to find new treatment targets and indicators for brain illnesses. Through the use of genetic data in clinical trials, they have improved patient classification, resulting in more fruitful and effective research initiatives.
In The Region, The North American Neurogenomics Market Holds A Significant Revenue Share
The North American Neurogenomics market is expected to register the highest market share in revenue in the near future because of its substantial R&D expenditures, established healthcare system, and presence of significant biotechnology firms. The need for advanced genetic diagnoses and individualized treatment options has significantly increased due to the rising prevalence of neurological diseases, including Parkinson's and Alzheimer's. Additionally, the region's dominant position in this sector is reinforced by regulatory body support and accelerated approval processes for genomic medicines, positioning it as a hub for neurogenomics advances. In addition, Asia Pacific is projected to grow rapidly in the global Neurogenomics market, driven by a growing patient population, rising healthcare spending, and growing awareness. The integration of neurogenomics in this field is accelerating due to advancements in sequencing techniques and government programs that support genomics-focused healthcare. Additionally, the growing number of neurological diseases and the availability of reasonably priced genetic testing alternatives are expanding the application of neurogenomics.
Recent Development:
- In Feb 2022, The Montreal Neurological Institute-Hospital at McGill University (The Neuro) has announced a new research collaboration with Illumina, Takeda Development Center Americas, Inc., and Roche. The collaboration, propelled by Illumina's whole genome sequencing technology, will establish a robust drug development platform for neurological illnesses, including Parkinson's disease and REM sleep behavior disorders.
Neurogenomics Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 1.7 Bn |
|
Revenue Forecast In 2034 |
USD 7.3 Bn |
|
Growth Rate CAGR |
CAGR of 16.2% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Offering, Application, And End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Danaher Corporation, Qiagen N.V., Agilent Technologies Inc., Oxford Nanopore Technologies Plc., Revvity Inc., Pacific Biosciences of California Inc. and MGI Tech Co. Ltd. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
